Literature DB >> 26637977

Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Mary J Gray1, Peter Kannu2, Swarkar Sharma3, Christine Neyt1, Dongping Zhang3, Nandina Paria3, Philip B Daniel1, Heather Whetstone4, Hans-Georg Sprenger1, Philipp Hammerschmidt1, Angela Weng4, Lucie Dupuis5, Rebekah Jobling5, Roberto Mendoza-Londono5, Michael Dray6, Peiqiang Su7, Megan J Wilson8, Raj P Kapur9, Edward F McCarthy10, Benjamin A Alman11, Andrew Howard12, Gino R Somers13, Christian R Marshall14, Simon Manners15, Adrienne M Flanagan16, Karl E Rathjen17, Lori A Karol17, Haemish Crawford15, David M Markie18, Jonathan J Rios19, Carol A Wise20, Stephen P Robertson1.   

Abstract

The periosteum contributes to bone repair and maintenance of cortical bone mass. In contrast to the understanding of bone development within the epiphyseal growth plate, factors that regulate periosteal osteogenesis have not been studied as intensively. Osteofibrous dysplasia (OFD) is a congenital disorder of osteogenesis and is typically sporadic and characterized by radiolucent lesions affecting the cortical bone immediately under the periosteum of the tibia and fibula. We identified germline mutations in MET, encoding a receptor tyrosine kinase, that segregate with an autosomal-dominant form of OFD in three families and a mutation in a fourth affected subject from a simplex family and with bilateral disease. Mutations identified in all families with dominant inheritance and in the one simplex subject with bilateral disease abolished the splice inclusion of exon 14 in MET transcripts, which resulted in a MET receptor (MET(Δ14)) lacking a cytoplasmic juxtamembrane domain. Splice exclusion of this domain occurs during normal embryonic development, and forced induction of this exon-exclusion event retarded osteoblastic differentiation in vitro and inhibited bone-matrix mineralization. In an additional subject with unilateral OFD, we identified a somatic MET mutation, also affecting exon 14, that substituted a tyrosine residue critical for MET receptor turnover and, as in the case of the MET(Δ14) mutations, had a stabilizing effect on the mature protein. Taken together, these data show that aberrant MET regulation via the juxtamembrane domain subverts core MET receptor functions that regulate osteogenesis within cortical diaphyseal bone.
Copyright © 2015 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26637977      PMCID: PMC4678433          DOI: 10.1016/j.ajhg.2015.11.001

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  52 in total

1.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

Authors:  P Peschard; T M Fournier; L Lamorte; M A Naujokas; H Band; W Y Langdon; M Park
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

2.  Periosteal bone formation--a neglected determinant of bone strength.

Authors:  Ego Seeman
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

3.  Familial congenital bowing of the tibia with pseudarthrosis and pectus excavatum: report of a kindred.

Authors:  R K Beals; W Fraser
Journal:  J Bone Joint Surg Am       Date:  1976-06       Impact factor: 5.284

4.  Osteofibrous dysplasia: two affected male sibs and an unrelated girl with bilateral involvement.

Authors:  Alasdair G W Hunter; James Jarvis
Journal:  Am J Med Genet       Date:  2002-09-15

5.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Authors:  Patrick C Ma; Takashi Kijima; Gautam Maulik; Edward A Fox; Martin Sattler; James D Griffin; Bruce E Johnson; Ravi Salgia
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Authors:  Selma Pennacchietti; Paolo Michieli; Maria Galluzzo; Massimiliano Mazzone; Silvia Giordano; Paolo M Comoglio
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

7.  Met and Hgf signaling controls hypaxial muscle and lateral line development in the zebrafish.

Authors:  Lynn Haines; Christine Neyt; Philippe Gautier; David G Keenan; Robert J Bryson-Richardson; Georgina E Hollway; Nicolas J Cole; Peter D Currie
Journal:  Development       Date:  2004-09-01       Impact factor: 6.868

8.  A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.

Authors:  Pascal Peschard; Noboru Ishiyama; Tong Lin; Stan Lipkowitz; Morag Park
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

9.  Osteofibrous dysplasia of the tibia and fibula.

Authors:  M Campanacci; M Laus
Journal:  J Bone Joint Surg Am       Date:  1981-03       Impact factor: 5.284

10.  Met signaling mutants as tools for developmental studies.

Authors:  C Ponzetto; G Panté; C Prunotto'; A Ieraci; F Maina
Journal:  Int J Dev Biol       Date:  2000       Impact factor: 2.203

View more
  3 in total

1.  Bilateral Symmetric Sporadic Osteofibrous Dysplasia: an Unusual Case.

Authors:  Asit Ranjan Mridha; Anubhav Narwal; Adarsh Barwad; Venkatesan Sampat Kumar; Shivanand Gamanagatti; Prashant Ramteke
Journal:  Indian J Surg Oncol       Date:  2020-10-08

2.  The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms.

Authors:  Kym M Boycott; Philippe M Campeau; Heather E Howley; Paul Pavlidis; Sanja Rogic; Christine Oriel; Jason N Berman; Robert M Hamilton; Geoffrey G Hicks; Howard D Lipshitz; Jean-Yves Masson; Eric A Shoubridge; Anne Junker; Michel R Leroux; Christopher R McMaster; Jaques L Michaud; Stuart E Turvey; David Dyment; A Micheil Innes; Clara D van Karnebeek; Anna Lehman; Ronald D Cohn; Ian M MacDonald; Richard A Rachubinski; Patrick Frosk; Anthony Vandersteen; Richard W Wozniak; Izabella A Pena; Xiao-Yan Wen; Thierry Lacaze-Masmonteil; Catharine Rankin; Philip Hieter
Journal:  Am J Hum Genet       Date:  2020-02-06       Impact factor: 11.025

3.  MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Authors:  Lisa Pei Chu; Debra Franck; Christine A Parachoniak; Jeffrey P Gregg; Michael G Moore; D Gregory Farwell; Shyam Rao; Andreas M Heilmann; Rachel L Erlich; Jeffrey S Ross; Vincent A Miller; Siraj Ali; Jonathan W Riess
Journal:  Oncologist       Date:  2019-08-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.